Connect Biopharma reports positive Phase 2 asthma, COPD data for rademikibart
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
SEC filing (4)
3 stories
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
SEC filing (4)
The company said rademikibart cut treatment failure by 81% and new exacerbations by 85% versus placebo in the Seabreeze STAT COPD trial, and plans to seek FDA alignment on Phase 3.
SEC filing
The company said rademikibart cut treatment failures by 66% versus placebo, though the result missed statistical significance, while lung function improved significantly at Day 7.
SEC filing